Biomarkers to predict the clinical efficacy of bevacizumab in cancer - The Lancet Oncology
Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice | SpringerLink
Amino acid sequence of variable heavy and light domains of RhumAb VEGF... | Download Scientific Diagram
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Frontiers | Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma
A549 xenograft tumors exhibited moderate resistance to bevacizumab... | Download Scientific Diagram
Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab | Eye
IMGt Protein displays of the VH and V-KAPPA domains of the bevacizumab... | Download Scientific Diagram
Sci. Pharm. | Free Full-Text | A New Practice to Monitor the Fabrication Process of Fab-Targeting Ligands from Bevacizumab by LC-MS: Preparation and Analytical Characterization
Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy | BMC Medical Genetics | Full Text
Structure–function relationships of the variable domains of monoclonal antibodies approved for cancer treatment
Optimization of Heavy Chain and Light Chain Signal Peptides for High Level Expression of Therapeutic Antibodies in CHO Cells | PLOS ONE
Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Impl
Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology | Future Oncology
Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin™ Fab - ScienceDirect
Molecules | Free Full-Text | Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma
FDA Briefing Document Oncologic Drugs Advisory Committee July 13, 2017 BLA 761028 ABP215, a proposed biosimilar to Avastin (beva
Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer | Cell Death & Disease
A Rational Sequencing of Anti-Angiogenic Agents as Second-Line Treatment Choice for mCRC Patients Progressing After a Bevacizumab-Based First Line | Published in healthbook TIMES Oncology Hematology
Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial | Breast Cancer Research | Full Text
Structure and mechanism of action of Bevacizumab. The humanised... | Download Scientific Diagram
A Rational Sequencing of Anti-Angiogenic Agents as Second-Line Treatment Choice for mCRC Patients Progressing After a Bevacizumab-Based First Line | Published in healthbook TIMES Oncology Hematology
